[1] |
Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti⁃immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR[J]. Allergy, 2004,59(7):709⁃717. doi: 10.1111/j.1398⁃9995.2004.00550.x.
|
[2] |
Hutyrová B, Bystroň J, Czech anti⁃IgE registry collaborators. The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real⁃life experience from the Czech anti⁃IgE registry[J]. Postepy Dermatol Alergol, 2018,35(5):510⁃515. doi: 10.5114/ada.2018.77243.
|
[3] |
Velling P, Skowasch D, Pabst S, et al. Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow⁃up of omalizumab therapy[J]. Eur J Med Res, 2011,16(9):407⁃410. doi: 10.1186/2047⁃783x⁃16⁃9⁃407.
|
[4] |
Rafi A, Do LT, Katz R, et al. Effects of omalizumab in patients with food allergy[J]. Allergy Asthma Proc, 2010,31(1):76⁃83. doi: 10.2500/aap.2010.31.3304.
|
[5] |
中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南(2018版)[J]. 中华皮肤科杂志, 2019,52 (1):1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001
|
[6] |
中华医学会变态反应分会呼吸过敏学组(筹), 中华医学会呼吸病学分会哮喘学组. 中国过敏性哮喘诊治指南(第一版,2019年)[J]. 中华内科杂志, 2019,58(9):636⁃655. doi: 10. 3760/cma.j.issn.0578⁃1426.2019.09.004.
|
[7] |
中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 变应性鼻炎诊断和治疗指南(2015年, 天津)[J] . 中华耳鼻咽喉头颈外科杂志, 2016,51 (1):6⁃24. doi: 10.3760/cma.j.issn.1673⁃0860.2016.01.004.
|
[8] |
中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020,53(2):81⁃88. doi: 10.35541/cjd.20191000.
|
[9] |
Licari A, Manti S, Marseglia A, et al. Food allergies: current and future treatments[J]. Medicina (Kaunas), 2019,55(5):120. doi: 10.3390/medicina55050120.
|
[10] |
于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证[J]. 中华皮肤科杂志, 2020,53(7):533⁃538. doi: 10. 35541/cjd.20191190.
|
[11] |
Zhou X, Ding FM, Lin JT, et al. Validity of asthma control test for asthma control assessment in Chinese primary care settings[J]. Chest, 2009,135(4):904⁃910. doi: 10.1378/chest.08⁃0967.
|
[12] |
Bousquet PJ, Combescure C, Neukirch F, et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines[J]. Allergy, 2007,62(4):367⁃372. doi: 10.1111/ j.1398⁃9995.2006.01276.x.
|
[13] |
Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis[J]. Clin Exp Allergy, 1991,21(1):77⁃83. doi: 10.1111/j.1365⁃2222.1991.tb00807.x.
|
[14] |
Crisafulli G, Caminiti L, Chiera F, et al. Omalizumab in children with severe allergic disease: a case series[J]. Ital J Pediatr, 2019,45(1):13. doi: 10.1186/s13052⁃019⁃0602⁃5.
|
[15] |
Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE⁃mediated) asthma[J]. Allergy, 2011,66(5):671⁃678. doi: 10. 1111/j.1398⁃9995.2010.02522.x.
|
[16] |
Li J, Kang J, Wang C, et al. Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a randomized phaseⅢ study[J]. Allergy Asthma Immunol Res, 2016,8(4):319⁃328. doi: 10.4168/aair.2016.8.4.319.
|
[17] |
Giubergia V, Ramírez Farías MJ, Pérez V, et al. Clinical impact of omalizumab treatment in children with severe asthma: report of a local experience[J]. Arch Argent Pediatr, 2019,117(2):e115⁃e120. doi: 10.5546/aap.2019.eng.e115.
|
[18] |
Pfaar O, Gehrt F, Li H, et al. Anti⁃IgE: a treatment option in allergic rhinitis?[J]. Allergol Select, 2021,5:119⁃127. doi: 10. 5414/ALX02205E.
|
[19] |
邱昕, 王洪田. 奥马珠单抗治疗变应性鼻炎的研究进展[J]. 中华耳鼻咽喉头颈外科杂志, 2015,50(2):166⁃168. doi: 10. 3760/cma.j.issn.1673⁃0860.2015.02.018.
|
[20] |
Corren J, Diaz⁃Sanchez D, Saxon A, et al. Effects of omalizumab, a humanized monoclonal anti⁃IgE antibody, on nasal reactivity to allergen and local IgE synthesis[J]. Ann Allergy Asthma Immunol, 2004,93(3):243⁃248. doi: 10.1016/S1081⁃1206(10)61495⁃0.
|
[21] |
Shinee T, Sutikno B, Abdullah B. The use of biologics in children with allergic rhinitis and chronic rhinosinusitis: current updates[J]. Pediatr Investig, 2019,3(3):165⁃172. doi: 10.1002/ped4.12146.
|
[22] |
Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti⁃IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2003,91(2):160⁃167. doi: 10.1016/S1081⁃1206(10)62171⁃0.
|
[23] |
Lacombe Barrios J, Bégin P, Paradis L, et al. Anti⁃IgE therapy and severe atopic dermatitis: a pediatric perspective[J]. J Am Acad Dermatol, 2013,69(5):832⁃834. doi: 10.1016/j.jaad.2013. 05.035.
|
[24] |
Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course ⁃ a randomized, placebo⁃controlled and double blind pilot study[J]. J Dtsch Dermatol Ges, 2010,8(12):990⁃998. doi: 10. 1111/j.1610⁃0387.2010.07497.x.
|
[25] |
Wollenberg A, Thomsen SF, Lacour JP, et al. Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence[J]. World Allergy Organ J, 2021,14(3):100519. doi: 10.1016/j.waojou.2021.100519.
|
[26] |
Andorf S, Purington N, Kumar D, et al. A Phase 2 randomized controlled multisite study using omalizumab⁃facilitated rapid desensitization to test continued vs. discontinued dosing in multifood allergic individuals[J]. EClinicalMedicine, 2019,7:27⁃38. doi: 10.1016/j.eclinm.2018.12.006.
|
[27] |
Marzano AV, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients[J]. Eur Acad Dermatol Venereol, 2019,33(5):918⁃924. doi: 10.1111/jdv.15350.
|
[28] |
Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change[J]. Allergy, 2018,73(3):705⁃712. doi:10.1111/all.13345.
|
[29] |
Stokes J. Anti⁃IgE treatment for disorders other than asthma[J]. Front Med (Lausanne), 2017,4:152. doi: 10.3389/fmed.2017. 00152.
|
[30] |
钟志娟, 王灵, 冯小伟, 等. 奥马珠单抗对儿童难治性过敏性哮喘伴鼻炎的疗效及其外周血tIgE和EOS计数的影响[J]. 中国免疫学杂志, 2022,38(4):469⁃473. doi: 10.3969/j.issn. 1000⁃484X.2022.04.016.
|
[31] |
刘蕊, 石磊, 翟钊.奥马珠单抗治疗过敏性鼻炎伴哮喘的疗效分析[J]. 中国处方药, 2021,19(4):79⁃80. doi: 10.3969/j.issn. 1671⁃945X.2021.04.039.
|